Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

MAY 01, 2013 - TheStreet

A Must Read - Share

Analysts' Actions: AMGN BIIB DWA FCX ULTI

NEW YORK (TheStreet) -- CHANGE IN RATINGS Amgen was upgraded at Goldman Sachs to buy from neutral. $130 price target. Company was also added to the Conviction Buy List, as the company has multiple potential catalysts, Goldman said. Biogen Idec was downgraded at Goldman Sachs to neutral from buy. $215 price target. Valuation call, as the stock is up 44% since December, Goldman said. ... Click to view a price quote on AMGN. Click to research the Drugs industry.

Tags: Analysts' Actions: AMGN BIIB DWA FCX ULTI,  Amgen Latest News